200 related articles for article (PubMed ID: 36627334)
1. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality.
Ukrainskaya VM; Musatova OE; Volkov DV; Osipova DS; Pershin DS; Moysenovich AM; Evtushenko EG; Kulakovskaya EA; Maksimov EG; Zhang H; Rubtsov YP; Maschan MA; Stepanov AV; Gabibov AG
Sci Rep; 2023 Jan; 13(1):463. PubMed ID: 36627334
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.
Zhu X; Hu H; Xiao Y; Li Q; Zhong Z; Yang J; Zou P; Cao Y; Meng F; Li W; You Y; Guo AY; Zhu X
Cancer Lett; 2022 Jun; 536():215668. PubMed ID: 35367518
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
[TBL] [Abstract][Full Text] [Related]
4. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
5.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
8. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
[TBL] [Abstract][Full Text] [Related]
9. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
11. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
13. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
[No Abstract] [Full Text] [Related]
14. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
[TBL] [Abstract][Full Text] [Related]
15. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
[TBL] [Abstract][Full Text] [Related]
16. Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells.
Li D; Xu Q; Hu Y; Wang W; Xie S; Zhao C; Liu H
J Leukoc Biol; 2022 Oct; 112(4):913-918. PubMed ID: 35338522
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
18. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
[TBL] [Abstract][Full Text] [Related]
19. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
20. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
